Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant 2016 Jan;51(1):83-8
Date
09/15/2015Pubmed ID
26367222Pubmed Central ID
PMC4570237DOI
10.1038/bmt.2015.203Scopus ID
2-s2.0-84953366034 (requires institutional sign-in at Scopus site) 28 CitationsAbstract
Allogeneic hematopoietic cell transplantation is associated with late adverse effects of therapy, including secondary solid cancers. Most reports address risk factors; however, outcomes after secondary solid cancer development are incompletely described. Our objective was to estimate survival probabilities for transplant recipients dependent on secondary solid cancer subtype. We used a previously identified and published cohort who developed secondary solid cancers following allogeneic transplant. Follow-up for these 112 previously identified patients was extended and their survival probabilities were studied. Median duration of follow-up from the development of secondary cancer for survivors was 11.9 years (range: 0.8-23.4) and 75% were followed >7.0 years. The 5- and 10-year overall survival probabilities were 50% (95% confidence interval (CI): 41-60) and 46% (95% CI: 37-57), respectively. Overall survival varied by secondary cancer type. Secondary cancer was the cause of death in most patients who died following development of melanoma, central nervous system, oral cavity, thyroid, lung, lower gastrointestinal tract and bone cancers. Extended follow-up allowed for the most comprehensive longitudinal evaluation to date of this rare condition. These findings will enhance clinicians' ability to predict outcomes and counsel transplant survivors who develop secondary solid cancers.
Author List
Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BEAuthors
Ruta Brazauskas PhD Associate Professor in the Data Science Institute department at Medical College of WisconsinJ. Douglas Rizzo MD, MS Director, Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin
Bronwen E. Shaw MBChB, PhD Center Director, Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Child
Child, Preschool
Disease-Free Survival
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Humans
Infant
Male
Middle Aged
Neoplasms, Second Primary
Organ Specificity
Retrospective Studies
Survival Rate
